Related Experiment Video
Updated: Jul 16, 2026
A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
Published on: April 26, 2015
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
Willem J Remme1, Christian Torp-Pedersen, John G F Cleland
1Sticares Cardiovascular Research Institute, Rhoon, The Netherlands. w.j.remme@sticares.org
Insights
Carvedilol demonstrated superior vascular protection compared to metoprolol tartrate in heart failure patients. This suggests carvedilol offers a broader protective effect against major vascular events.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Carvedilol's full adrenergic blockade and antioxidative properties may offer vascular protection beyond metoprolol's beta-1 blockade.
- Understanding these mechanisms is crucial for optimizing heart failure (HF) treatment.
Purpose of the Study:
- To investigate if carvedilol's vascular protective effects contribute to its superior outcomes in HF compared to metoprolol tartrate.
- To analyze vascular end points in the COMET (Carvedilol Or Metoprolol European Trial) study.
Main Methods:
- A double-blind, randomized trial involving 3,029 HF patients (ischemic and idiopathic cardiomyopathy).
- Patients were assigned to carvedilol (n=1,511) or metoprolol tartrate (n=1,518) for 58 months.
- Vascular endpoints included cardiovascular death, stroke, myocardial infarction (MI), and unstable angina.
Main Results:
- Carvedilol significantly reduced myocardial infarctions (MI) (HR 0.71, p=0.03) and unstable angina (HR 0.71, p=0.049) compared to metoprolol.
- Combined cardiovascular death or nonfatal MI was reduced by 19% with carvedilol (HR 0.81, p=0.0009).
- Fatal MI or stroke was significantly lower with carvedilol (HR 0.46, p=0.0002), as was death after nonfatal MI or stroke (HR 0.66, p=0.0086).
Conclusions:
- Carvedilol significantly improved vascular outcomes compared to metoprolol tartrate in patients with heart failure.
- The findings suggest a comprehensive protective effect of carvedilol against major vascular events in HF management.
Objectives:
We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study.
Background:
Full adrenergic blockade by carvedilol and additional (e.g., antioxidative) properties may lead to vascular protection relative to beta-1 blockade alone, and contribute to its efficacy in HF treatment.
Methods:
Three thousand twenty-nine patients with HF due to ischemic (51%) or idiopathic cardiomyopathy (44%) were randomized double-blind to carvedilol (n = 1,511) or metoprolol (n = 1,518) and followed for 58 months. Vascular end points were cardiovascular death, stroke, stroke death, myocardial infarction (MI), and unstable angina.
Results:
The effect of carvedilol on cardiovascular death improved consistently in subgroups with prespecified baseline variables. Myocardial infarctions were reported in 69 carvedilol and 94 metoprolol patients (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.52 to 0.97, p = 0.03). Cardiovascular death or nonfatal MI combined were reduced by 19% in carvedilol (HR 0.81, 95% CI 0.72 to 0.92, p = 0.0009 vs. metoprolol). Unstable angina was reported as an adverse event in 56 carvedilol and in 77 metoprolol patients (HR 0.71, 95% CI 0.501 to 0.998, p = 0.049). A stroke occurred in 65 carvedilol and 80 metoprolol patients (HR 0.79, 95% CI 0.57 to 1.10). Stroke or MI combined occurred in 130 carvedilol and 168 metoprolol patients (HR 0.75, 95% CI 0.60 to 0.95, p = 0.015), and fatal MI or fatal stroke occurred in 34 carvedilol and in 72 metoprolol patients (HR 0.46, 95% CI 0.31 to 0.69, p = 0.0002). Death after a nonfatal MI or stroke occurred in 61 of 124 carvedilol and in 106 of 160 metoprolol patients (HR 0.66, 95% CI 0.48 to 0.90, p = 0.0086).
Conclusions:
Carvedilol improves vascular outcomes better than metoprolol. These results suggest a ubiquitous protective effect of carvedilol against major vascular events.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:28Antihypertensive Drugs: Types of β-Blockers
01:26Coronary Artery Disease IV: Preventive Measures